The high frequency, acute and sudden beginning, fast clinical dynamics, and critical complications make acute limb ischemia one of the leading causes for invalidization and mortality in worldwide. It takes emergency diagnostics, operative or endovascular treatment to clear blood vessels, suture them and provide enough blood pressure to the region in ischemia. It has been a long time since R. Virchow marked the tree main etiopathogenic causes for blood vessel thrombosis. Now we have found new cause leading to acute limb ischemia (AAI)-COVID-19 endotheliitis with the development of viral endotheliitis. Guidelines recommendations for treatment of COVID-19-induced ALI include thrombectomy, high doses intravenous corticosteroids, and high-molecular-weight heparin. Nevertheless, in our short 1-year experience with such cases, we noticed the high share of reoperations and high risk of limb amputations and lethal outcome.
Malas, M.B.; Naazie, I.N.; Elsayed, N.; Mathlouthi, A.; Marmor, R.; Clary, B. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis. EClinicalMedicine 2020
Thachil, J.; Tang, N.; Gando, S.; Falanga, A.; Cattaneo, M.; Levi, M.; Clark, C.; Iba, T. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J. Thromb. Haemost. 2020, 18, 1023–1026. [CrossRef
Tang, N.; Bai, H.; Chen, X.; Gong, J.; Li, D.; Sun, Z. Anticoagulant treatment is a
ssociated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J. Thromb. Haemost. 2020, 18, 1094–1099. [CrossRef]
Ozsu, S.; Gunay, E.; Konstantinides, S.V. A review of venous thromboembolism in COVID-19: A clinical perspective. Clin. Respir. J. 2021, 15, 506–512. [CrossRef]
